No abstract

The clinical course of lymphoma depends on the indolent or aggressive nature of the disease. Hence, the optimal management of lymphoma needs a correct diagnosis and classification as B cell, T-cell or natural killer (NK)/T-cell as well as indolent or high-grade type lymphoma. The current consensus statement, developed by experts in the field across India, is intended to help healthcare professionals manage lymphomas in adults over 18 years of age. However, it should be noted that the information provided may not be appropriate to all patients and individual patient circumstances may dictate alternative approaches. The consensus statement discusses the diagnosis, staging and prognosis applicable to all subtypes of lymphoma, and detailed treatment regimens for specific entities of lymphoma including diffuse large B-cell lymphoma, Hodgkin’s lymphoma, follicular lymphoma, T-cell lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, Burkitt’s lymphoma, and anaplastic large cell lymphoma.

The epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of EGFR-mutant nonsmall cell lung cancer (NSCLC). These EGFR TKIs demonstrate a different adverse event (AE) profile as compared to conventional chemotherapy agents. They are more commonly associated with cutaneous AEs and diarrhea while hematological AEs occurred commonly with chemotherapy agents. These AEs are the extension of pharmacological effect and occur as a result of blockade of EGFR-regulated pathways in the skin and gastrointestinal tract. This review article sheds light on the safety profile of first-, second-, and third-generation EGFR TKIs based on data obtained from several clinical trials conducted in NSCLC patients and highlights trials comparing these agents with the conventional chemotherapy agents. The strategies to manage EGFR TKI-related AEs are also reviewed.

Introduction: Cardiovascular causes contribute toward a large proportion of increased morbidity and mortality in patients with chronic kidney disease (CKD). Cardiac disease is the major cause of death in the CKD population. Materials and methods:The present study was undertaken for documentation of various cardiovascular abnormalities in 50 patients with CKD at RajaRajeswari Medical College & Hospital, Bengaluru, Karnataka, India, using electrocardio graphy (ECG) and echocardiography as investigation proce dures. The present study is a descriptive crosssectional study and data collected were analyzed by frequency, percentage, chisquared test, and pvalue which is the left ventricular (LV) diastolic dysfunction. Pericardial effusion and conduction abnormalities are more common in patients of CKD. Results:The ECG was normal in 12 out of 50 cases of CKD (24%), left ventricular hypertrophy (LVH) present in 14 out of 50 (28%), left axis deviation in 8 out of 50 (16%), conduction disturbances in 11 out of 50 (22%), ischemia in 10 out of 50 (20%), arrhythmias in 1 out of 50 (2%), and P mitrale was found in 3 out of 50 cases (6%). The most common ECG change asso ciated with cases with CKD was LVH (28%). The most common abnormality found on echocardiography in CKD cases under the study was LVH (56%) followed by diastolic dysfunction (38%). Conclusion:The LVH is the commonest abnormality observed in CKD both on ECG and echocardiography. Echocardiography is a more sensitive diagnostic procedure to detect LVH. After LVH other most common abnormalities found on Echocardiography in CKD patients on haemodialysis were pericardial effusion and conduction abnormalities.

No abstract